ALN-CC5-003 EudraCT Termination Summary

Title of Trial:	A Phase 2, Open-label, Single Dose, Study of Subcutaneously Administered ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria who are Inadequate Responders to Eculizumab
EudraCT Number:	2016-002943-40
Date of Termination:	22-November-2016
Protocol Number:	ALN-CC5-003
Rationale:	The Sponsor terminated the study to allow for a re-evaluation of how best to develop ALN-CC5 to address the unmet needs for patients with paroxysmal nocturnal hemoglobinuria. No patients were consented, screened or dosed in the trial. The study was not terminated on the grounds of safety.